Unlike well described hereditary cancer risk syndromes such as BRCA1/2 [24–26], this is the first study to evaluate the prognosis of cancer in patients with germline pathogenic variants in PTEN (i.e. in individuals with PHTS). This evidence concerns the gene PTEN and cancer.